
Functional interaction between the von Hippel-Lindau protein and Androgen receptor in ccRCC




<u>Antonella Falconieri¹, Chiara Boschelle¹, Giovanni Minervini¹, Silvio C.E. Tosatto^{1,2}, Maria Pennuto^{1,3}</u>

¹ Department of Biomedical Science, University of Padua, Italy; ² CNR Institute of Neuroscience, Padua, Italy; ³ Veneto Institute of Molecular Medicine, Padua, Italy


antonella.falconieri@unipd.it

BACKGROUND

More than 80% of clear cell renal cell carcinomas (ccRCC) are linked to loss of function (LOF) mutations of the von Hippel-Lindau protein (pVHL). Males have a higher risk of developing renal cancer compared to females, implying a role for androgens in the etiology of the disease. The main mediator of androgen signaling is Androgen Receptor (AR). AR and pVHL have been reported to structurally and functionally interact with each other. However, how the functional relationship between AR and pVHL is regulated and how it impacts ccRCC gender bias is unknown. In this study, we used molecular, cellular and biochemical analysis to characterize pVHL/AR interaction



Both pVHL isoforms interact with AR



in different ccRCC cell models.

AIM

To elucidate whether the interplay between AR and pVHL has a role in ccRCC sex discrepancy





Figure 1. Protein-protein interaction network centered around AR and **pVHL** Connections between nodes represent experimental evidence while bubbles are for proteins forming the network. Proteins are grouped by shared biological pathways and colored accordingly. A green line is used to underline the novel association between AR and pVHL.

Figure 2. Co-ip experiments in HEK293T cells showing protein-protein interactions between AR and pVHL isoforms A) AR and pVHL30 (full-length isoform) – B) AR and pVHL19 (shorter isoform) As reported in panels A and B these physical associations are regulated by androgens binding suggesting that AR in its unliganded state forms a complex with pVHL which detach upon DHT treatment (n=3).

KDa



RESULTS

IB: a-flag

IB: antiHA

25


IP

(anti-flag)

pVHL influences AR protein turnover in an isoform-specific manner

Male:female = 2:1

EXPERIMENTAL MODEL



SW839 (pVHL-)

2h

β-Tub

4h

Time (h)

CHX


150

GNT 100 20

NT

AR

SW839-pVHL30



Time (h)

SW839-pVHL19




Figure 4. Turnover experiments in ccRCC cell lines showing pVHL isoform-specific impact on AR stability pVHL affects AR protein stability in an isoform-specific manner. Indeed, pVHL30 seems to increase the AR protein turnover, while pVHL19 lacks this function yielding to AR stabilization (n=3).

pVHL effects on cell proliferation are reduced by AR activation




Figure 5. Proliferation assays measuring both pVHL and androgens effect on ccRCC cell lines pVHL isoforms expression decrease ccRCC cell proliferation which is recovered by AR activation upon treatment with 10 nM DHT. This finding suggests that AR in its active state may act as pro-proliferative factor in renal cancer (n=3).

DHT= dihydrotestosterone

24h 72h 96h 48h Time (h)



To sum up:

• pVHL isoforms interact with AR regulating its protein stability in an isoform-specific fashion: pVHL30 increases the AR protein turnover while pVHL19 lacks this function leading to AR stabilization;

pVHL doesn't change AR accumulation upon DHT treatment;

• pVHL expression in RCC cells reduces cell proliferation which is recovered by AR activation upon ligand binding.

